CN117143823A - 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用 - Google Patents
一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用 Download PDFInfo
- Publication number
- CN117143823A CN117143823A CN202311173537.3A CN202311173537A CN117143823A CN 117143823 A CN117143823 A CN 117143823A CN 202311173537 A CN202311173537 A CN 202311173537A CN 117143823 A CN117143823 A CN 117143823A
- Authority
- CN
- China
- Prior art keywords
- cells
- chimeric antigen
- antigen receptor
- memory
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 83
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title claims abstract description 58
- 102000016914 ras Proteins Human genes 0.000 title claims abstract description 18
- 102200006531 rs121913529 Human genes 0.000 title claims abstract description 18
- 230000008685 targeting Effects 0.000 title claims abstract description 8
- 238000011161 development Methods 0.000 title abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 40
- 239000000427 antigen Substances 0.000 claims abstract description 24
- 102000036639 antigens Human genes 0.000 claims abstract description 24
- 108091007433 antigens Proteins 0.000 claims abstract description 24
- 239000012634 fragment Substances 0.000 claims abstract description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 8
- 230000011664 signaling Effects 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 22
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 12
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 12
- 102000003812 Interleukin-15 Human genes 0.000 claims description 10
- 108090000172 Interleukin-15 Proteins 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 10
- -1 ICOS Proteins 0.000 claims description 9
- 102000013462 Interleukin-12 Human genes 0.000 claims description 9
- 108010065805 Interleukin-12 Proteins 0.000 claims description 9
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 9
- 210000004700 fetal blood Anatomy 0.000 claims description 9
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 8
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 8
- 239000012190 activator Substances 0.000 claims description 8
- 239000002609 medium Substances 0.000 claims description 8
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 7
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 6
- 102000000588 Interleukin-2 Human genes 0.000 claims description 6
- 108010002350 Interleukin-2 Proteins 0.000 claims description 6
- 241000713666 Lentivirus Species 0.000 claims description 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 4
- 102100032937 CD40 ligand Human genes 0.000 claims description 4
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 4
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 3
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 3
- 239000012737 fresh medium Substances 0.000 claims description 3
- 230000003834 intracellular effect Effects 0.000 claims description 3
- 230000004068 intracellular signaling Effects 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 210000002993 trophoblast Anatomy 0.000 claims description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100037904 CD9 antigen Human genes 0.000 claims description 2
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims description 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 claims description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims description 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 2
- 101000589305 Homo sapiens Natural cytotoxicity triggering receptor 2 Proteins 0.000 claims description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 2
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 2
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims description 2
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims description 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 2
- 230000006051 NK cell activation Effects 0.000 claims description 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 2
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 2
- 102100032851 Natural cytotoxicity triggering receptor 2 Human genes 0.000 claims description 2
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims description 2
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 210000001778 pluripotent stem cell Anatomy 0.000 claims 1
- 230000008901 benefit Effects 0.000 abstract description 9
- 230000002147 killing effect Effects 0.000 abstract description 6
- 230000000139 costimulatory effect Effects 0.000 abstract description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract description 3
- 238000002659 cell therapy Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 30
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 30
- 238000010361 transduction Methods 0.000 description 12
- 230000026683 transduction Effects 0.000 description 12
- 102000011786 HLA-A Antigens Human genes 0.000 description 11
- 108010075704 HLA-A Antigens Proteins 0.000 description 11
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 108700038581 vectofusin-1 Proteins 0.000 description 4
- 102000003810 Interleukin-18 Human genes 0.000 description 3
- 108090000171 Interleukin-18 Proteins 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000005909 tumor killing Effects 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 2
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 2
- 102100030704 Interleukin-21 Human genes 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 108010074108 interleukin-21 Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000581 natural killer T-cell Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101100355569 Dictyostelium discoideum rabV gene Proteins 0.000 description 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 238000002407 reforming Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种基于TCR单链可变区的靶向肿瘤新抗原RAS(G12V)的嵌合抗原受体记忆NK细胞的研制及其应用。所述的嵌合抗原受体包括单链TCR的可变区、铰链区、跨膜区、共刺激结构域、信号传导结构域,必要时,可串联分选标签。所述NK细胞为记忆NK细胞。所述TCR的可变区包括具有α链可变区的Vα片段和具有β链可变区的Vβ片段,所述Vα片段的氨基酸序列如SEQ ID NO:1所示,所述Vβ片段的氨基酸序列如SEQ ID NO:2所示。本发明构建的嵌合抗原受体具有TCR的靶点优势,能够识别肿瘤新抗原。而NK细胞缺乏完整的CD3信号通路,通过CAR的信号通路,再与记忆NK细胞结合,可以有效性解决TCR‑T、CAR‑T、CAR‑NK、TCR‑NK的局限性。同时嵌合抗原受体记忆NK细胞能在体内持续存活,在抗原再次刺激时,能够产生更强大的杀伤作用,在防止肿瘤复发方面起到一定的作用。是一种靶点范围广、通用性强、安全、有效且低成本的细胞治疗产品。
Description
技术领域
本发明涉及生物技术领域,具体涉及一种基于TCR单链可变区的靶向肿瘤新抗原的嵌合抗原受体记忆NK细胞的研制及其应用
背景技术
实体肿瘤发病率更高、异质性强、致病机制和肿瘤微环境极其复杂。虽然CAR-T在实体肿瘤的临床研究风生水起,但是目前尚未取得突破性进展,在其众多技术瓶颈中,靶点的突破无疑是至关重要的。当前实体肿瘤的靶点主要基于肿瘤相关抗原的(TAA)的开发,这类靶点存在脱靶现象、肿瘤清除不彻底、因正常组织受损引起副作用和不良反应等问题。因此针对实体肿瘤的CAR-T需要通过肿瘤特异性靶点(TSA)的优化选择实现治疗上的突破。
传统CAR技术只能识别细胞膜蛋白,但实体肿瘤缺乏有效的膜蛋白。仅仅靠一个或几个膜蛋白靶点无法彻底解决实体肿瘤异质性难题,即靶点的缺失导致肿瘤的复发。T细胞抗原受体(TCR)的作用是识别抗原。理论上可以识别肿瘤细胞内所有多肽(蛋白),其抗原识别范围远远广于CAR。肿瘤新抗原是一种来源于非同义突变的肿瘤特异性抗原,具有广泛性和特异性。随着个体化、多靶点的肿瘤新抗原(肿瘤特异性抗原,TSA)的发现,使得T细胞抗原受体(TCR)技术重新纳入研究人员视野。
相较于T细胞,NK细胞作为靶向杀伤载体在肿瘤治疗中更具有优势。除了获得与传统自体CAR-T治疗肿瘤相当的疗效外,还具有无免疫排斥、无严重CRS反应等特征,实现了临床治疗有效性、安全性、通用性,并且可以大大降低生产成本及制备风险。基于上述众多优势,目前嵌合抗原受体NK细胞技术正在逐步替代嵌合抗原受体T细胞技术。
由于NK细胞缺乏完整的CD3信号通路,因此TCR不能够直接“安装”于NK细胞载体中,为了解决上述难题,有文献报道将NK细胞进行CD3分子改造,即在“安装”TCR分子同时,“安装”CD3的四个亚基CD3ζ、CD3γ、CD3ε、CD3δ,但这种改造后的结构分子量大,不利于转导,且缺乏第二信号通路。也有文献报道通过对TCR进行改造,构建出sc-TCRVaVbCb突变体,将sc-TCRVaVbCb基因被连接到CD3-z上,诱导嵌合TCRab基因的异二聚和T细胞激活。虽然对TCR的a链进行了优化,但依然存在分子量大及第二信号通路问题。Chandran SS等人报道,将TCR的a链在其TM区域上被截断,在其恒定域上添加了半胱氨酸,并且两个链通过2A肽序列连接。CD28作为跨膜区(TM),并连接了CD3和CD28作为第二刺激信号。虽然解决了第二信号通路问题,但分子量依然很大,不利于转导的问题没有解决。
肿瘤复发仍然是细胞治疗面临的一个难点。NK细胞在细胞因子或在病毒感染的情况下能产生记忆样特性,在抗原再次刺激时能产生更强烈的抗肿瘤效应,在肿瘤复发方面具有一定的优势。
发明内容
发明目的:针对上述技术问题,本专利技术通过对TCR的两条肽链进行改造,只保留α、β两条肽链的可变区(V区),然后借鉴CAR的结构构建了嵌合抗原受体记忆NK细胞,解决了CAR-T细胞的靶点识别问题及TCR的信号传导通路问题,具有多靶点识别和信号传导的双重特性,抗原识别区只保留了α、β两条肽链的可变区,分子量大大缩小,不仅能够识别HLA递呈的抗原多肽,还有利于转导。将本专利中构建的嵌合抗原制备成脐血来源的嵌合抗原受体记忆NK细胞,能在体内持续存活,在抗原再次刺激时,能够产生更强大的杀伤作用,在防止肿瘤复发方面起到一定的作用,是一种靶点范围广、通用性强、安全、有效且低成本的细胞治疗产品。
技术方案:为了达到上述发明目的,本发明所采用的技术方案如下:
一种基于TCR单链可变区的靶向RAS(G12V)的嵌合抗原受体记忆NK细胞的研制及其应用。其特征在于所述嵌合抗原受体包括抗原结合结构域,铰链区、跨膜结构域、共刺激结构域、信号传导结构域和/或分选标签。所述NK细胞为记忆NK细胞。
所述嵌合抗原受体的抗原结合结构域为TCR单链抗体的可变区。所述TCR单链抗体的可变区包括具有α链可变区的Vα片段和β链可变区的Vβ片段,所述Vα片段的氨基酸序列如SEQ ID NO:1
(GEQVEQRPPHLSVREGDSAVITCTYTDPNSYYFFWYKQEPGASLQLLMKVFSSTEINEGQGFTVLLNKKDKRLSLNLTAAHPGDSAAYFCAVSGGTNSAGNKLTFGIGTRVLVRP)所示,所述Vβ片段的氨基酸序列如SEQ ID NO:2所示。
(ETAVFQTPNYHVTQVGNEVSFNCKQTLGHDTMYWYKQDSKKLLKIMFSYNNKQLIVNETVPRRFSPQSSDKAHLNLRIKSVEPEDSAVYLCASSRDWGPAEQFFGPGTRLTVLE)
所述α链可变区的Vα片段和β链可变区的Vβ片段是通过linker连接。其连接顺序为Vα-linker-Vβ或者Vβ-linker-Vα。所述linker的序列如SEQ ID NO:3(SGGGSGGGGSGGGGSGGGGSGGGSLQ)、SEQ ID NO:4(GGGGS)、SEQ ID NO:5(GGGGSGGGGSGGGGSGGGGS)、SEQ ID NO:6(EAAAK)、SEQ ID NO:7(EAAAKEAAAKEAAAK)、SEQ IDNO:8(GSADDAKKDAAKKDGKS)、SEQ ID NO:9(SSADDAKKDAAKKDDAKKDDAKKDA);
优选的,所述linker为:SEQ ID NO:4(GGGGS)
所述的铰链区选自CD8α、CD28、CD4、CD5、CD134、CD137、ICOS铰链区中的一种或多种的组合。
跨膜结构域选自CD3ζ、CD4、CD5、CD8、CD8α、CD9、CD16、CD19、CD22、CD28、CD33、CD37、CD45、ICOS、CD134、CD137、CD154、NKG2D、2B4和DNAM1中的一种或多种的跨膜结构域。
所述共刺激信号传导区包含共刺激分子的细胞内结构域,所述共刺激分子选自:CD27、CD3ζ、CD3γ、CD3δ、CD3ε、CD5、CD22、CD79a、CD79b、CD66d、CD2、CD4、CD5、CD28、CD30、CD40、CD134、CD137、ICOS、CD154、4-1BB、OX40、CD7、LIGHT、NKG2C、B7-H3、DAP10、DAP12、NKp44、NKG2D、NKp46,NKp30、TNFR家族(4-1BB、OX40和CD27)或SLAM相关受体家族(2B4)中的一种或多种。
优选地,所述铰链区为CD8α(CD8αSEQ ID NO:10)
ACCACCACCCCCGCCCCCCGCCCCCCCACCCCCGCCCCCACCATCGCCAGCCAGCCCCTGAGCCTGCGCCCCGAGGCCTGCCGCCCCGCCGCCGGCGGCGCCGTGCACACCCGCGGCCTGGACTTCGCCTGCGACATCTACATCTGGGCCCCCCTGGCCGGCACCTGCGGCGTGCTGCTGCTGAGCCTGGTGATCACC。
所述跨膜结构域为NKG2D(SEQ ID NO:11)
CCATTTTTTTTCTGCTGCTTCATCGCTGTAGCCATGGGAATCCGTTTCATTATTATGGTAGCA。
所述胞内信号传导结构域选用CD3ζ结构域(SEQ ID NO:12)
CGCGTGAAATTCAGCCGCAGCGCAGATGCTCCAGCCTACCAGCAGGGGCAGAACCAGCTCTACAACGAACTCAATCTTGGTCGGAGAGAGGAGTACGACGTGCTGGACAAGCGGAGAGGACGGGACCCAGAAATGGGCGGGAAGCCGCGCAGAAAGAATCCCCAAGAGGGCCTGTACAACGAGCTCCAAAAGGATAAGATGGCAGAAGCCTATAGCGAGATTGGTATGAAAGGGGAACGCAGAAGAGGCAAAGGCCACGACGGACTGTACCAGGGACTCAGCACCGCCACCAAGGACACCTATGACGCTCTTCACATGCAGGCCCTGCCGCCTCGGTGA
优选的,所述胞内共刺激结构域选用4-1BB,(SEQ ID NO:13)
AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTG
所述的NK细胞可以来自于健康成人脐带血提取的NK细胞、外周血提取的NK细胞、胚胎干细胞(ESC)及诱导多能干细胞(iPSC)产生的NK细胞。优选地,所述的NK细胞为脐带血提取的NK细胞。
所述嵌合抗原受体记忆NK细胞可由如下方法制备:
S1、取健康供者的脐带血分离出NK细胞,并在细胞因子刺激下被激活。
S2、激活后的NK细胞通过一定的方式除去激活物,并更换成新鲜的培养基。
S3、用带有嵌合抗原受体基因的慢病毒感染激活后的NK细胞。
S4、感染后的NK细胞在24小时后更换成新鲜的培养基。
S5、加入辐照的滋养层细胞继续培养。
S6、收获细胞。
所述的刺激NK细胞的激活物为IL2、IL12、IL15、IL18的混合物。优选地,所述激活物浓度为500U/ml的IL2、10ng/ml的IL12、15ng/ml的IL15、50ng/ml的IL18的混合物。
上述S2中所述的NK细胞被刺激16-36小时后,除去激活物,并更换成新鲜的培养基。优选的,NK细胞激活24小时后,300g、5min离心后,用PBS或者生理盐水洗2遍,更换成含IL15(200U)的新鲜KBM581或者X-VIVO15培养基,并加入5%-10%人AB血清。
上述S3中带有嵌合抗原受体CSR基因的慢病毒是通过四质粒悬浮细胞包装,且所用的包膜蛋白为BaEV、BaEVRT、BaEVRless、RD114、RDpro、VSVG、RabV、Cacal-G、MOKV、PRYV-G等,优选地,所选的包膜蛋白为BaEVRless(SEQ ID NO:14)
MGFTTKIIFLYNLVLVYAGFDDPRKAIELVQKRYGRPCDCSGGQVSEPPSDRVSQVTCSGKTAYLMPDQRWKCKSIPKDTSPSGPLQECPCNSYQSSVHSSCYTSYQQCRSGNKTYYTATLLKTQTGGTSDVQVLGSTNKLIQSPCNGIKGQSICWSTTAPIHVSDGGGPLDTTRIKSVQRKLEEIHKALYPELQYHPLAIPKVRDNLMVDAQTLNILNATYNLLLMSNTSLVDDCWLCLKLGPPTPLAIPNFLLSYVTRSSDNISCLIIPPLLVQPMQFSNSSCLFSPSYNSTEEIDLGHVAFSNCTSITNVTGPICAVNGSVFLCGNNMAYTYLPTNWTGLCVLATLLPDIDIIPGDEPVPIPAIDHFIYRPKRAIQFIPLLAGLGITAAFTTGATGLGVSVTQYTKLSNQLISDVQILSSTIQDLQDQVDSLAEVVLQNRRGLDLLTAEQGGICLALQEKCCFYVNKSGIVRDKIKTLQEELERRRKDLASNPLWTGLQGLLPYLLPFLGPLLTLLLLLTIGPCIFNRLTAFINDKLNIIHAM
上述S3中所述的转导是在NK细胞被激活后5-10天,优选地,NK细胞被激活后D5天转导。转导时需去除人AB血清并加入助染剂Vectofusin-1或者Ploybrene。优选地,所用助染剂为Vectofusin-1。
上述S5中所述的滋养层细胞为转导了IL21、41BB、CD64和CD86的经辐照的K562细胞。其中IL21的序列为SEQ ID NO:15所示;
MRSSPGNMERIVICLMVIFLGTLVHKSSSQGQDRHMIRMRQLIDIVDQLKNYVNDLVPEFLPAPEDVETNCEWSAFSCFQKAQLKSANTGNNERIINVSIKKLKRKPPSTNAGRRQKHRLTCPSCDSYEKKPPKEFLERFKSLLQKMIHQHLSSRTHGSEDS;
CD137的序列为SEQ ID NO:16所示:
ATGGGAAACAGCTGTTACAACATAGTAGCCACTCTGTTGCTGGTCCTCAACTTTGAGAGGACAAGATCATTGCAGGATCCTTGTAGTAACTGCCCAGCTGGTACATTCTGTGATAATAACAGGAATCAGATTTGCAGTCCCTGTCCTCCAAATAGTTTCTCCAGCGCAGGTGGACAAAGGACCTGTGACATATGCAGGCAGTGTAAAGGTGTTTTCAGGACCAGGAAGGAGTGTTCCTCCACCAGCAATGCAGAGTGTGACTGCACTCCAGGGTTTCACTGCCTGGGGGCAGGATGCAGCATGTGTGAACAGGATTGTAAACAAGGTCAAGAACTGACAAAAAAAGGTTGTAAAGACTGTTGCTTTGGGACATTTAACGATCAGAAACGTGGCATCTGTCGACCCTGGACAAACTGTTCTTTGGATGGAAAGTCTGTGCTTGTGAATGGGACGAAGGAGAGGGACGTGGTCTGTGGACCATCTCCAGCCGACCTCTCTCCGGGAGCATCCTCTGTGACCCCGCCTGCCCCTGCGAGAGAGCCAGGACACTCTCCGCAGATCATCTCCTTCTTTCTTGCGCTGACGTCGACTGCGTTGCTCTTCCTGCTGTTCTTCCTCACGCTCCGTTTCTCTGTTGTTAAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGTGA
CD64的序列为SEQ ID NO:17所示
MWFLTTLLLWVPVDGQVDTTKAVITLQPPWVSVFQEETVTLHCEVLHLPGSSSTQWFLNGTATQTSTPSYRITSASVNDSGEYRCQRGLSGRSDPIQLEIHRGWLLLQVSSRVFTEGEPLALRCHAWKDKLVYNVLYY;
CD86的序列为SEQ ID NO:18所示;
MDPQCTMGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGVMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQPPPDHIPWITAVLPTVIICVMVFCLILWKWKKKKRPRNSYKCGTNTWEREESEQTKKREKIHIPERSDEAQRVFKSSKTSSCDKSDTCF;同时还要添加IL12(500U)及5%人AB血清。
具体的,可按如下方法制备:
(1)加入浓度为500U/ml的IL2、10ng/ml的IL12、15ng/ml的IL15、50ng/ml的IL18的混合物刺激NK细胞;
(2)15-20小时后,用PBS将上述激活物去除,更换成含IL15(200U)的新鲜KBM581或者X-VIVO15培养基,并加入5%-10%人AB血清;
(3)被激活后4-6天,用HLA-A*1101和RAS(G12V)质粒包装的慢病毒转导NK细胞;转导时需去除人AB血清并加入助染剂Vectofusin-1;转导后24小时换成新鲜的含IL12(500U)、5%人AB血清的X-VIVO15培养基继续培养;每隔1-2天进行补液,培养14天,获得嵌合抗原受体记忆NK细胞。
本发明所提供的一种基于TCR单链可变区的靶向肿瘤新抗原RAS(G12V)的嵌合抗原受体NK细胞的研制,其中基于TCR单链可变区的单链抗体适用于所有肿瘤新抗原。在细胞方面,还使用于除NK细胞外的其他免疫细胞,如T细胞、γδT细胞、NKT细胞等
本发明提供一种嵌合抗原受体记忆NK的制备方法及在防止肿瘤复发中的应用。
鉴于现有技术存在的问题,本发明参考TCR在结构上与抗体分子高度相似(TCR有两条链构成)的特点,借鉴单链抗体的结构,构建单链可变区TCR。此改造后单链可变区TCR仅含有α的可变区片段(Vα)和β的可变区片段(Vβ),大大缩短了质粒的长度,有利于质粒的转导。同时借鉴CAR的分子结构,建立一种基于单链可变区TCR的新型嵌合抗原受体。此嵌合抗原受体既保留了TCR识别靶点的优势,能识别肿瘤特异性的抗原,同时拥有CAR的信号通路。本发明中的嵌合抗原受体细胞,可以为NK细胞、T细胞、γδT细胞、NKT细胞等免疫细胞,尤其适用于NK细胞。因为NK细胞的寿命短,毒性风险相对较低,且NK细胞来源广泛,如NK92细胞系、外周血单个核细胞(PBMCs)、脐带血(UCB)和诱导多能干细胞(iPSCs)等,可以提供一种“现成的”产品,消除了对困扰当前CAR-T细胞治疗的个性化和患者特异性产品的需求,且成本大大降低。为解决实体肿瘤的异质性和复杂性提供治疗策略。此专利方法中的嵌合抗原受体NK细胞是一款目前最理想的实体肿瘤细胞治疗产品,实现对肿瘤细胞的无死角杀伤,使广大肿瘤患者受益。
有益效果:与现有技术相比,本发明具有以下优势:
(1)借鉴单链抗体结构,构建仅含有TCR可变区的单链TCR,大大减小了单链的分子量,且保留了TCR识别靶点的优势,能识别肿瘤特异性的抗原。同时借鉴CAR分子结构,拥有CAR的信号通路,确保嵌合抗原受体的靶向性。
(2)NK细胞不受MHC识别的限制,异体来源NK细胞移植几乎不会诱发移植物抗宿主病(GVHD),不会引起CRS,且分泌的PD-1水平较低,免疫抑制作用较小。同时,记忆NK细胞在抗原再次刺激时能产生更强烈的抗肿瘤效应,将TCR的优势应用于NK细胞。在肿瘤复发方面具有一定的优势。
(3)脐血NK来源广,成本低,具备通用型的特点,可作为“现货型”产品使用。
(4)嵌合抗原受体记忆NK不仅能够治疗肿瘤,在防止肿瘤复发方面在存在一定的作用。
附图说明
图1:嵌合抗原受体的结构示意图。
图2:嵌合抗原受体-NK细胞的感染效率及扩增倍数。
图3:嵌合抗原受体NK对肿瘤细胞的杀伤作用。
图4:IFNγ的表达量。
具体实施方式
为了使本发明更加容易理解,下面结合具体实例,进一步阐述本发明。
鉴于肿瘤新抗原RAS(G12V)在包括肺癌,结直肠癌和胰腺癌中高频突变及HLA-A*11:01在亚洲人群中的高频占比,我们选择HLA-A*11:01/RAS(G12V)作为靶点,并成功筛选出具有高亲和力的抗体,开发设计出嵌合抗原受体NK细胞。前期已经初步完成其功能和安全性验证,显示出较好的对表达HLA-A*01:01/RAS(G12V)靶点的肿瘤细胞的杀伤性以及安全性。本实施例选用HLA-A*01:01/RAS(G12V)的肿瘤细胞。但此实施例不用于限制本发明,仅用于说明本发明。
实施例1嵌合抗原的序列选择
鉴于肿瘤新抗原RAS(G12V)在包括肺癌,结直肠癌和胰腺癌中高频突变及HLA-A*11:01在亚洲人群中的高频占比,我们选择HLA-A*11:01和RAS(G12V)作为靶点,筛选出具有高亲和力的抗体,经过不断的实验摸索,筛选出由Vα和Vβ片段组成的单链TCR。构建的嵌合抗原受体包括抗原识别结构域、铰链区、跨膜区、共刺激结构域、信号传导结构域、分选标签(图1)。其中抗原识别结构域识别由HLA-A*1101递呈RAS(G12V)突变多肽的TCR的α和β可变区的单链。Vα片段的氨基酸序列如SEQ ID NO:1所示,Vβ片段的氨基酸序列如SEQ ID NO:2所示。Vα片段与Vβ片段通过接头Linker连接;铰链区为CD8α,如SEQ ID NO:10所示;跨膜区为NKG2D,如SEQ ID NO:11所示,共刺激结构域选用4-1BB,如SEQ ID NO:12所示;胞内信号传导结构域选用CD3ζ结构域,如SEQ ID NO:13所示。
实施例2序列载体的构建
利用PCR技术将嵌合抗原受体的核苷酸序列扩增出来,然后将嵌合抗原受体序列克隆至载体中,挑选阳性克隆并测序,鉴定正确的质粒。扩大培养后,提取质粒,获得所需的质粒载体。
实施例3慢病毒的制备
(1)采用四质粒悬浮细胞体系包装慢病毒。
(2)在转染前24小时,将传3代以上的悬浮细胞调整密度达到3.5–5.5×106viablecells/ml。24小时后将上述细胞直接用培养基稀释至3.5×106viable cells/ml,过夜生长,活率应≥95%。
(3)将扩增后的细胞用新鲜培养基将细胞稀释至4.7×106viable cells/ml的密度,然后加入Supplement,轻轻旋转摇瓶混匀。
(4)制备DNA/转染试剂复合物。
(5)将DNA/转染试剂复合物缓慢转移至摇瓶中,在此过程中轻轻旋转摇瓶。
(6)培养箱摇床培养。
(7)转染后5-6h,加入4%的转染增强剂
(8)转染后48-55h收病毒后,将收集到的上清培养基5000rpm、4℃离心10min,弃沉淀留上清,并将上清用0.45um的滤膜过滤。
(9)将上述病毒上清液加入到含有蔗糖溶液的离心管中,4℃,25,000rpm.(82,700g)离心2小时,使用超高速离心机进行病毒浓缩。
(10)弃上清,用不含钙和镁的PBS重悬沉淀,即得病毒悬液。分装后冻存于-80℃待用;
(11)利用QPCR检测病毒滴度,病毒滴度可达10的8次方。
实施例4嵌合抗原受体记忆NK细胞的制备
(1)脐带血来自健康供者,采用淋巴细胞分离术分离出PBMC。
(2)用NK细胞分离试剂盒分选出NK细胞。
(3)加入浓度为500U/ml的IL2、10ng/ml的IL12、15ng/ml的IL15、50ng/ml的IL18的混合物刺激NK细胞。
(4)18小时后,用PBS将上述激活物去除,更换成含IL15(200U)的新鲜KBM581或者X-VIVO15培养基,并加入5%-10%人AB血清。
(5)被激活后D5天,用HLA-A*1101和RAS(G12V)质粒包装的慢病毒转导NK细胞。转导时需去除人AB血清并加入助染剂Vectofusin-1。转导后24小时换成新鲜的含IL12(500U)、5%人AB血清的X-VIVO15培养基继续培养。
(6)每隔1-2天进行补液,培养14天,获得嵌合抗原受体记忆NK细胞。利用流式细胞术检测感染效率和嵌合抗原受体记忆NK细胞的扩增能力。
(7)同步用正常因子培养法制备CAR-NK细胞、嵌合抗原受体NK细胞。
结果显示,经体外扩增14天,嵌合抗原受体记忆NK扩增近400倍(图2A)。对照组CAR-NK细胞、嵌合抗原受体NK、嵌合抗原受体记忆NK的转导效率分别为18.54%、40.54%和52.18%(图2B),嵌合抗原受体记忆NK的转导效率明显高于CAR-NK细胞组。
实施例5嵌合抗原受体记忆NK对体外肿瘤杀伤效果的评估
为了验证嵌合抗原受体记忆NK对表达HLA-A*1101和RAS(G12V)的靶细胞的杀伤能力。将嵌合抗原受体记忆NK细胞与表达HLA-A*1101和RAS(G12V)的靶细胞按照2:1、5:1、10:1效靶比共培养,24小时后,检测靶下拨的裂解情况及细胞因子的分泌情况。结果如图3A-C及图4所示,嵌合抗原受体记忆NK对过表达HLA-A*1101和RAS(G12V)的靶细胞具有较强的杀伤作用,且能分泌更多的IFNγ。。
以上实施方式仅用于说明本发明,而非对本发明的限制。尽管参照实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,对本发明的技术方案进行各种组合、修改或者等同替换,都不脱离本发明技术方案的精神和范围,均应涵盖在本发明的权利要求范围中。
Claims (10)
1.一种基于TCR单链可变区的靶向RAS(G12V)的嵌合抗原受体记忆NK细胞,其特征在于,所述嵌合抗原受体记忆NK细胞可由如下方法制备:
S1、分离出NK细胞,并在细胞因子刺激下被激活;
S2、激活后的NK细胞通过一定的方式除去激活物,并更换成新鲜的培养基;
S3、用带有嵌合抗原受体基因的慢病毒感染激活后的NK细胞;
S4、感染后的NK细胞在24小时后更换成新鲜的培养基;
S5、加入辐照的滋养层细胞继续培养;
S6、收获细胞;
其中,所述嵌合抗原记忆NK细胞包含基于TCR单链可变区的靶向RAS-G12V的嵌合抗原受体,所述嵌合抗原受体包括抗原结合结构域、铰链区、跨膜区、共刺激结构域、信号传导结构域,其中抗原结合结构域为TCR单链抗体的可变区,具有α链可变区的Vα片段和β链可变区的Vβ片段,所述Vα片段的氨基酸序列如SEQ ID NO:1所示,所述Vβ片段的氨基酸序列如SEQID NO:2所示;所述NK细胞来自于健康成人脐带血提取的NK细胞、外周血提取的NK细胞、市售的胚胎干细胞或诱导多能干细胞产生的NK细胞。
2.根据权利要求1所述的嵌合抗原受体记忆NK细胞,其特征在于,所述α链可变区的Vα片段和β链可变区的Vβ片段是通过linker连接,其连接顺序为Vα-linker-Vβ或者Vβ-linker-Vα;所述嵌合抗原受体可选的包括分选标签。
3.根据权利要求1所述的嵌合抗原受体记忆NK细胞,其特征在于,所述铰链区选自CD8α、CD28、CD4、CD5、CD134、CD137、ICOS铰链区中的一种或多种的组合;跨膜区选自CD3ζ、CD4、CD5、CD8、CD8α、CD9、CD16、CD19、CD22、CD28、CD33、CD37、CD45、ICOS、CD134、CD137、CD154、NKG2D、2B4和DNAM1中的一种或多种的跨膜结构;所述共刺激信号传导区分子选自:CD27、CD3ζ、CD3γ、CD3δ、CD3ε、CD5、CD22、CD79a、CD79b、CD66d、CD2、CD4、CD5、CD28、CD30、CD40、CD134、CD137、ICOS、CD154、4-1BB、OX40、CD7、LIGHT、NKG2C、B7-H3、DAP10、DAP12、NKp44、NKG2D、NKp46,NKp30、TNFR家族或SLAM相关受体家族中的一种或多种。
4.根据权利要求1所述的嵌合抗原受体记忆NK细胞,其特征在于,所述铰链区为CD8α,如SEQ ID NO:10所示;所述跨膜区为NKG2D,如SEQ ID NO:11所示;所述胞内信号传导结构域为CD3ζ结构域,如SEQ ID NO:12所示;所述胞内共刺激结构域为4-1BB,如SEQ ID NO:13所示。
5.根据权利要求1-4任一项所述的嵌合抗原受体记忆NK细胞,其特征在于,S1中刺激NK细胞的细胞因子为IL2、IL12、IL15、IL18的混合物。
6.根据权利要求5所述的嵌合抗原受体记忆NK细胞,其特征在于,所述细胞因子浓度为500U/ml的IL2、10ng/ml的IL12、15ng/ml的IL15、50ng/ml的IL18的混合物。
7.根据权利要求6所述的嵌合抗原受体记忆NK细胞,其特征在于,S2中所述的NK细胞被刺激16-36小时后,除去激活物,并更换成新鲜的培养基。
8.根据权利要求6所述的嵌合抗原受体记忆NK细胞,其特征在于,NK细胞激活24小时后,300g、5min离心后,用PBS或者生理盐水洗2遍,更换成含200U的IL15新鲜KBM581或者X-VIVO15培养基,并加入5%-10%人AB血清。
9.权利要求1-9任一项所述的嵌合抗原记忆NK细胞在制备防止实体癌复发的药物中的应用。
10.权利要求9所述的应用,所述实体癌为胰腺癌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311173537.3A CN117143823A (zh) | 2023-09-11 | 2023-09-11 | 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311173537.3A CN117143823A (zh) | 2023-09-11 | 2023-09-11 | 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117143823A true CN117143823A (zh) | 2023-12-01 |
Family
ID=88898653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311173537.3A Pending CN117143823A (zh) | 2023-09-11 | 2023-09-11 | 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117143823A (zh) |
-
2023
- 2023-09-11 CN CN202311173537.3A patent/CN117143823A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105624107B (zh) | 一种多种淋巴细胞亚群的扩增方法及其应用 | |
WO2016130598A1 (en) | Bi-specific chimeric antigen receptor and uses thereof | |
CN108948211B (zh) | 一种基于靶向gd2的嵌合抗原受体及其应用 | |
US20190367876A1 (en) | Methods of transducing and expanding immune cells and uses thereof | |
CN110964121B (zh) | 一种分泌il-7、il-15因子的cd19-car-t细胞及其应用 | |
KR20200000495A (ko) | 키메라 항원 수용체 단백질을 코딩하는 핵산 및 키메라 항원 수용체 단백질을 발현하는 t 림프구 | |
CN114656569B (zh) | 包含nkg2d结构域的多特异性嵌合受体和其使用方法 | |
CN110564695A (zh) | 靶向前列腺癌的增强型car-t细胞及其制备方法和药物 | |
CN112029729B (zh) | Cd19和cd22双靶点嵌合抗原受体nk细胞及其应用 | |
CN107245106B (zh) | 一种基于cd10的嵌合抗原受体及其应用 | |
CN109652380B (zh) | 基于碱基编辑靶向LewisY的CAR-T细胞及其制备方法和应用 | |
WO2022257835A1 (en) | Cd7-based humanized chimeric antigen receptor and use thereof | |
CN114456270B (zh) | 一种gd2嵌合抗原受体及其应用 | |
JP2021519107A (ja) | 膜結合型IL−10を発現する遺伝子的にリプログラミングされたTreg | |
CN117567650B (zh) | 共表达细胞间黏附分子icam2的car-t细胞及其制备方法与应用 | |
KR20200113211A (ko) | 키메라 항원 수용체를 발현하는 조절 t 세포 | |
CN108699163B (zh) | 一种多基因重组嵌合抗原受体分子及其应用 | |
US20240009310A1 (en) | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 | |
US20230321242A1 (en) | Chimeric antigen receptor (car)-expressing cells recognizing cea | |
CN115724978A (zh) | 一种抗psma单链抗体及与其相关的嵌合抗原受体和应用 | |
CN117143823A (zh) | 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用 | |
CN107916269B (zh) | 靶向cd19的tcr基因、制备方法、具有该基因的质粒、试剂盒及应用 | |
CN114891123B (zh) | 一种基于CD79b人源化抗体的嵌合抗原受体及其应用 | |
CN117567651B (zh) | 协同表达血管内皮黏附分子vcam1的嵌合抗原受体及其应用 | |
WO2024011335A1 (zh) | 经修饰的免疫细胞 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |